Abstract
Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date1,2. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / isolation & purification*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Neutralizing / immunology
-
Antibodies, Neutralizing / isolation & purification
-
Betacoronavirus / drug effects*
-
Betacoronavirus / immunology
-
Betacoronavirus / pathogenicity
-
COVID-19
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / immunology
-
Coronavirus Infections / virology
-
Humans
-
Pandemics
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / virology
-
Protein Binding
-
SARS-CoV-2
-
Spike Glycoprotein, Coronavirus / antagonists & inhibitors*
-
Spike Glycoprotein, Coronavirus / immunology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Neutralizing
-
Spike Glycoprotein, Coronavirus
-
spike protein, SARS-CoV-2